Inhibition of nuclear factor-κB attenuates atherosclerosis in apoE/LDLR - double knockout mice

Journal of Physiology and Pharmacology

Volumn 56, Issue 3, 2005, Pages 483-489

  Jawien J ^a   Gajda, M ^a   Mateuszuk, L ^a   Olszanecki, R ^a   Jakubowski, A ^a   Szlachcic, A ^a   Korabiowska, M ^b   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

apoE LDLR knockout mice; Atherosclerosis; PDTC

Indexed keywords

AMMONIUM PYRROLIDINEDITHIOCARBAMATE; APOLIPOPROTEIN E; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE TARGETING; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OXIDATION; PROTEIN TARGETING; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PYRROLIDINES; RECEPTORS, LDL; THIOCARBAMATES; TRIGLYCERIDES;

EID: 26044464591     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
2. Guzik TJ, Olszanecki R, Sadowski J et al. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J Physiol Pharmacol 2005; 56: 313-323.
3. Salem JE, Cabrera ME, Chandler MP et al. Step and ramp induction of myocardial ischaemia: comparison of in vivo and in silico results. J Physiol Pharmacol 2004; 55: 519-536.
4. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-4475.
5. Plump AS, Smith JD, Hayek T, Aalto - Setela K et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E - deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
6. Savla U. At the heart of atherosclerosis. Nat Med 2002; 8: 1209.
7. Ishibashi S, Herz J, Maeda N, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus - mediated gene delivery. J Clin Invest 1993; 92: 883-893.
8. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 1994; 91: 4431-4435.
9. Witting PK, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Eriksson AW, Stocker R. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J 1999; 13: 667-675.
10. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apoE knockout mice. J Clin Invest 1998; 102: 910-918.
11. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E - knockout mice. Cardiovasc Res 2003; 59: 234-240.
12. Robertson AKL, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-1350.
13. Collins T, Cybulsky MI. NF-kappaB: a pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-264.
14. Hishikawa K, Nakaki T. NF-κB as a therapeutic target for cardiovascular disease. Heart Drug 2002; 2: 303-311.
15. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Pharmacol Physiol 2003; 54: 469-487.
16. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kB as a mediator of initial lesion development in atherosclerosis. TRENDS Mol Med 2003; 9: 549-557.
17. Zingarelli B, Sheehan M, Wong HR. Nuclear factor-κB as a therapeutic target in critical care medicine. Crit Care Med 2003; 31 (suppl.): S105-S111.
18. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001; 38: 307-314.
19. Jakubowski A, Olszanecki R, Chlopicki S. Involvement of platelet activating factor in immediate heart response to lipopolysaccaride. J Physiol Pharmacol 2004; 55: 409-421.
20. Schaffer S, Schmitt-Schilling S, Muller WE, Eckert GP. Antioxidant properties of Mediterrean food plant extracts: geographical differences. J Physiol Pharmacol 2005; 56 (suppl.1): 115-124.
21. 2 mechanism. J Physiol Pharmacol 2004; 55: 537-550.
22. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM et al. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003; 57: 168-177.
23. Somers PK, Medford RM, Saxena U. Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Rad Biol Med 2000; 28: 1532-1537.
24. Moellering D, McAndrew J, Jo H, Darley-Usmar VM. Effects of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress. Free Rad Biol Med 1999; 26: 1138-1145.
25. Ross R. Cell biology of atherosclerosis. Ann Rev Physiol 1995; 57: 791-804.
26. Hancock WW, Buelow R, Sayegh H, Turka LA. Antibody-induced transplant atherosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4: 1392-1396.
27. Naksahima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-140.